Randomized trial comparing liposomal daunorubicin with idarubicin as induction for pediatric acute myeloid leukemia: Results from study AML-BFM 2004

Blood

Volumn 122, Issue 1, 2013, Pages 37-43

  Creutzig, Ursula ^a   Zimmermann, Martin ^a   Bourquin, Jean Pierre ^b   Dworzak, Michael N ^c   Fleischhack, Gudrun ^d   Graf, Norbert ^e   Klingebiel, Thomas ^f   Kremens, Bernhard ^d   Lehrnbecher, Thomas ^f   Von Neuhoff, Christine ^a   Ritter, Jörg ^g   Sander, Annette ^a   Schrauder, André ^h   Von Stackelberg, Arend ⁱ   Starý, Jan ^j   Reinhardt, Dirk ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d UNIVERSITY OF DUISBURG ESSEN   (Germany)

^e SAARLAND UNIVERSITY   (Germany)

^f UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^g UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^h UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

ⁱ CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^j UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CLADRIBINE; CYTARABINE; DAUNORUBICIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ETOPOSIDE; IDARUBICIN; ANTINEOPLASTIC ANTIBIOTIC; LIPOSOME;

ABSCESS; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT RESPIRATORY DISTRESS SYNDROME; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACTERIAL INFECTION; BLEEDING; BRAIN HEMORRHAGE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CARDIOMYOPATHY; CARDIOTOXICITY; CHILD; CHILDHOOD CANCER; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DRUG FATALITY; DRUG WITHDRAWAL; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; FUNCTIONAL DISEASE; HEART ARRHYTHMIA; HEART FUNCTION; HIGH RISK PATIENT; HUMAN; HYPOTENSION; INDUCTION CHEMOTHERAPY; LEUKEMIA RELAPSE; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; MYCOSIS; MYELODYSPLASTIC SYNDROME; NEUROTOXICITY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PNEUMONIA; PRESCHOOL CHILD; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SEPTICEMIA; SIDE EFFECT; SKIN TOXICITY; SKULL IRRADIATION; SURVIVAL RATE; SURVIVAL TIME; THROMBOEMBOLISM; TREATMENT DURATION; TREATMENT PLANNING; BONE MARROW; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECT; HEART DISEASE; MORTALITY; MULTIVARIATE ANALYSIS; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; SECOND CANCER; TREATMENT OUTCOME;

ADOLESCENT; ANTIBIOTICS, ANTINEOPLASTIC; BONE MARROW; CHILD; CHILD, PRESCHOOL; DAUNORUBICIN; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEART DISEASES; HUMANS; IDARUBICIN; LEUKEMIA, MYELOID, ACUTE; LIPOSOMES; MALE; MULTIVARIATE ANALYSIS; NEOPLASMS, SECOND PRIMARY; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; TREATMENT OUTCOME;

EID: 84883703682     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-02-484097     Document Type: Article

References (38)

1. Creutzig U, Zimmermann M, Ritter J, et al. Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials. Leukemia. 2005;19(12): 2030-2042. (Pubitemid 41741595)
2. Fernandez HF, Sun Z, Yao X, et al. Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med. 2009;361(13):1249-1259.
3. Löwenberg B, Ossenkoppele GJ, van Putten W, et al; Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON); German AML Study Group (AMLSG); Swiss Group for Clinical Cancer Research (SAKK) Collaborative Group. High-dose daunorubicin in older patients with acute myeloid leukemia [published correction appears in N Engl J Med 2010;362:1155]. N Engl J Med. 2009; 361(13):1235-1248.
4. van Dalen EC, van der Pal HJ, Caron HN, Kremer LC. Different dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapy. Cochrane Database Syst Rev. 2009 Oct 7;(4):CD005008.
5. van Dalen EC, Michiels EM, Caron HN, Kremer LC. Different anthracycline derivates for reducing cardiotoxicity in cancer patients. Cochrane Database Syst Rev. 2010 Mar 17;(3):CD005006.
6. Lipshultz SE, Adams MJ. Cardiotoxicity after childhood cancer: beginning with the end in mind. J Clin Oncol. 2010;28(8):1276-1281.
7. Kaspers GJ, Creutzig U. Pediatric acute myeloid leukemia: international progress and future directions. Leukemia. 2005;19(12):2025-2029. (Pubitemid 41741594)
8. Forssen EA, Tökès ZA. Use of anionic liposomes for the reduction of chronic doxorubicin-induced cardiotoxicity. Proc Natl Acad Sci U S A. 1981; 78(3):1873-1877. (Pubitemid 11114279)
9. Forssen EA, Coulter DM, Proffitt RT. Selective in vivo localization of daunorubicin small unilamellar vesicles in solid tumors. Cancer Res. 1992; 52(12):3255-3261.
10. Gill PS, Wernz J, Scadden DT, et al. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma. J Clin Oncol. 1996;14(8):2353-2364. (Pubitemid 26264888)
11. Levitt G. Cardioprotection. Br J Haematol. 1999; 106(4):860-869. (Pubitemid 29462996)
12. Pouna P, Bonoron-Adèle S, Gouverneur G, Tariosse L, Besse P, Robert J. Development of the model of rat isolated perfused heart for the evaluation of anthracycline cardiotoxicity and its circumvention. Br J Pharmacol. 1996;117(7): 1593-1599. (Pubitemid 26116789)
13. AML Collaborative Group. A systematic collaborative overview of randomized trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukaemia. Br J Haematol. 1998;103(1): 100-109.
14. Creutzig U, Ritter J, Zimmermann M, et al; AML-BFM Study Group. Idarubicin improves blast cell clearance during induction therapy in children with AML: results of study AML-BFM 93. Leukemia. 2001;15(3):348-354. (Pubitemid 32243767)
15. von Neuhoff C, Reinhardt D, Sander A, et al. Prognostic impact of specific chromosomal aberrations in a large group of pediatric patients with acute myeloid leukemia treated uniformly according to trial AML-BFM 98. J Clin Oncol. 2010;28(16):2682-2689.
16. Creutzig U, Zimmermann M, Lehrnbecher T, et al. Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98. J Clin Oncol. 2006;24(27):4499-4506. (Pubitemid 46646248)
17. Creutzig U, Zimmermann M, Bourquin JP, et al. CNS irradiation in pediatric acute myleoid leukemia: equal results by 12 or 18 Gy in studies AML-BFM98 and 2004. Pediatr Blood Cancer. 2011;57(6):986-992.
18. Klusmann JH, Reinhardt D, Zimmermann M, et al. The role of matched sibling donor allogeneic stem cell transplantation in pediatric high-risk acute myeloid leukemia: results from the AML-BFM 98 study. Haematologica. 2011;97(1):21-29.
19. Creutzig U, Zimmermann M, Reinhardt D, Dworzak M, Stary J, Lehrnbecher T. Early deaths and treatment-related mortality in children undergoing therapy for acute myeloid leukemia: analysis of the multicenter clinical trials AML-BFM 93 and AML-BFM 98. J Clin Oncol. 2004;22(21): 4384-4393. (Pubitemid 41185159)
20. Cheson BD, Cassileth PA, Head DR, et al. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol. 1990;8(5):813-819. (Pubitemid 20148273)
21. Kalbfleisch J, Prentice R. The Statistical Analysis of Failure Time Data. New York, NY: Wiley; 2002.
22. Freedman LS. Tables of the number of patients required in clinical trials using the logrank test. Stat Med. 1982;1(2):121-129. (Pubitemid 13146129)
23. Hempel G, Reinhardt D, Creutzig U, Boos J. Population pharmacokinetics of liposomal daunorubicin in children. Br J Clin Pharmacol. 2003;56(4):370-377. (Pubitemid 37188131)
24. Cortes J, Estey E, O'Brien S, et al. High-dose liposomal daunorubicin and high-dose cytarabine combination in patients with refractory or relapsed acute myelogenous leukemia. Cancer. 2001; 92(1):7-14. (Pubitemid 32623034)
25. Forssen EA, Ross ME. Daunoxome treatment of solid tumors: preclinical and clinical investigations. J Liposome Res. 1994;4(1): 481-512. (Pubitemid 24130557)
26. Reinhardt D, Hempel G, Fleischhack G, Schulz A, Boos J, Creutzig U. Liposomal daunorubicine combined with cytarabine in the treatment of relapsed/refractory acute myeloid leukemia in children [in German]. Klin Padiatr. 2002;214(4): 188-194. (Pubitemid 34925495)
27. Lange BJ, Dinndorf P, Smith FO, et al. Pilot study of idarubicin-based intensive-timing induction therapy for children with previously untreated acute myeloid leukemia: Children's Cancer Group Study 2941. J Clin Oncol. 2003;22(1):150-156.
28. Creutzig U, Zimmermann M, Ritter J, Henze G, Graf N, L? offler H, Schellong G. Definition of a standard-risk group in children with AML. Br J Haematol. 1999;104(3):630-639. (Pubitemid 29119294)
29. Wells RJ, Woods WG, Buckley JD, et al. Treatment of newly diagnosed children and adolescents with acute myeloid leukemia: a Children's Cancer Group study. J Clin Oncol. 1994;12(11):2367-2377. (Pubitemid 24346709)
30. Creutzig U, Zimmermann M, Bourquin JP, et al. Second induction with high-dose cytarabine and mitoxantrone: different impact on pediatric AML patients with t(8;21) and with inv(16). Blood. 2011; 118(20):5409-5415.
31. Tsukimoto I, Tawa A, Horibe K, et al. Risk-stratified therapy and the intensive use of cytarabine improves the outcome in childhood acute myeloid leukemia: the AML99 trial from the Japanese Childhood AML Cooperative Study Group. J Clin Oncol. 2009;27(24):4007-4013.
32. Abrahamsson J, Forestier E, Heldrup J, et al. Response-guided induction therapy in pediatric acute myeloid leukemia with excellent remission rate. J Clin Oncol. 2010;29(3):310-315.
33. Gibson BE, Webb DK, Howman AJ, De Graaf SS, Harrison CJ, Wheatley K; United Kingdom Childhood Leukaemia Working Group and the Dutch Childhood Oncology Group. Results of a randomized trial in children with acute myeloid leukaemia: medical research council AML12 trial. Br J Haematol. 2011;155(3):366-376.
34. Rubnitz JE, Inaba H, Dahl G, et al. Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. Lancet Oncol. 2010;11(6): 543-552.
35. Creutzig U, Diekamp S, Zimmermann M, Reinhardt D. Longitudinal evaluation of early and late anthracycline cardiotoxicity in children with AML. Pediatr Blood Cancer. 2007;48(7):651-662. (Pubitemid 46717611)
36. Lipshultz SE, Alvarez JA, Scully RE. Anthracycline associated cardiotoxicity in survivors of childhood cancer. Heart. 2007;94(4):525-533.
37. US Food and Drug Administration. FDA Statement on dexrazoxane. http://www.fda.gov/Drugs/DrugSafety/ucm263729.htm. Accessed July 20, 2011.
38. Kaspers GJ, Zimmermann M, Reinhardt D, et al. Improved outcome in pediatric relapsed acute myeloid leukemia: results of a randomized trial on liposomal daunorubicin by the International BFM Study Group. J Clin Oncol. 2013;31(5):599-607.